Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been given an average rating of “Buy” by the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $95.25.
Several brokerages have commented on JANX. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th.
Read Our Latest Stock Report on JANX
Insider Buying and Selling
Institutional Trading of Janux Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after purchasing an additional 1,574 shares during the period. US Bancorp DE raised its position in shares of Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after purchasing an additional 1,658 shares during the period. Russell Investments Group Ltd. raised its position in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $59,000. Finally, FNY Investment Advisers LLC raised its position in shares of Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after purchasing an additional 2,425 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.
Janux Therapeutics Price Performance
Shares of JANX opened at $23.24 on Friday. The firm’s 50 day moving average is $26.32 and its 200-day moving average is $35.31. The stock has a market capitalization of $1.38 billion, a P/E ratio of -17.09 and a beta of 2.96. Janux Therapeutics has a 12-month low of $22.48 and a 12-month high of $71.71.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 9.29%. As a group, equities research analysts forecast that Janux Therapeutics will post -1.38 EPS for the current fiscal year.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Recommended Stories
- Five stocks we like better than Janux Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.